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To date, survival data on risk factors for COVID-19 mortality in western Europe is limited,
and none of the published survival studies have used a competing risk approach. This study
aims to identify risk factors for in-hospital mortality in COVID-19 patients in the Netherlands,
considering recovery as a competing risk.
Methods
In this observational multicenter cohort study we included adults with PCR-confirmed
SARS-CoV-2 infection that were admitted to one of five hospitals in the Netherlands (March
to May 2020). We performed a competing risk survival analysis, presenting cause-specific
hazard ratios (HRCS) for the effect of preselected factors on the absolute risk of death and
recovery.
Results
1,006 patients were included (63.9% male; median age 69 years, IQR: 58–77). Patients
were hospitalized for a median duration of 6 days (IQR: 3–13); 243 (24.6%) of them died,
689 (69.9%) recovered, and 74 (7.4%) were censored. Patients with higher age (HRCS 1.10,
95% CI 1.08–1.12), immunocompromised state (HRCS 1.46, 95% CI 1.08–1.98), who used
anticoagulants or antiplatelet medication (HRCS 1.38, 95% CI 1.01–1.88), with higher
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modified early warning score (MEWS) (HRCS 1.09, 95% CI 1.01–1.18), and higher blood
LDH at time of admission (HRCS 6.68, 95% CI 1.95–22.8) had increased risk of death,
whereas fever (HRCS 0.70, 95% CI 0.52–0.95) decreased risk of death. We found no
increased mortality risk in male patients, high BMI or diabetes.
Conclusion
Our competing risk survival analysis confirms specific risk factors for COVID-19 mortality in
a the Netherlands, which can be used for prediction research, more intense in-hospital mon-
itoring or prioritizing particular patients for new treatments or vaccination.
Introduction
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated
coronavirus disease 2019 (COVID-19) causes significant morbidity and mortality worldwide.
The first laboratory-confirmed case of COVID-19 in the Netherlands was reported on Febru-
ary 27, 2020 [1]. The disease initially spread across the southern provinces and rapidly dissemi-
nated further throughout the country. Currently, the Netherlands is amidst a second wave of
infections and>350 thousand confirmed cases have been reported, including >7 thousand
deaths [2, 3].
Studies describing the clinical features of COVID-19 and risk factors associated with inci-
dence and timing of poor outcome have been extensively published [4], but survival data
regarding risk factors for COVID-19 mortality in north-western Europe is limited. Further-
more, to our knowledge, none of the published survival studies have considered recovery as
competing risk for mortality. Not taking competing risks into account leads to biased mortality
estimates and to overestimation of survival curves [5, 6]. Analyzing mortality data with a more
accurate competing risk analysis adds to the growing body of evidence on disease course and
risk factors of a poor COVID-19 outcome. More robust knowledge about these risk factors is
crucial to inform international prediction research [4]. In the current phase of the pandemic,
now specific vaccines are underway, correct identification of patients at risk of severe disease
and mortality is essential to prioritize patients for vaccination. In addition, while the virus still
circulates in the population, it can guide clinical decisions on close monitoring, ICU admission
or selection for new treatments. Therefore, this study aims to identify risk factors for in-hospi-
tal mortality in laboratory-confirmed COVID-19 patients in the Netherlands, using a compet-
ing risk approach.
Materials and methods
In this observational, multicenter cohort study, we consecutively included adult patients with
PCR-confirmed infection with SARS-CoV-2, who were admitted to one of five collaborating
hospitals in the region of Gelderland and North-Brabant for at least 24 hours between March
and May 2020. For the current analysis, we excluded patients if data regarding duration of hos-
pital admission were missing for patients who died or recovered. A flow chart of inclusion is
shown in S1 Fig. The study was approved by the institutional review board (IRB) of the Rad-
boud university medical center (number 2020–2923 and 2020–6344). According to the IRB,
only oral consent was required. Oral consent was obtained from all patients or their family
and documented in the electronic medical records.
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Data collection and definitions
We extracted routine data from the electronic medical records, including baseline patient
characteristics, information on clinical presentation, diagnostics, disease course, treatment
and outcome. All patient data were entered anonymously into a web-based electronic case
report form (using Castor Electronic Data Capture), only using a study identifier. The key
linking patient information to study ID was saved in a local, protected file in the participating
hospitals and not available to the researchers performing data analyses. Detailed methods on
data collection and definitions are described in our parallel publication in this issue. For the
current analysis, we used the Modified Early Warning Score (MEWS) as a summary measure
of abnormal vital signs, based on body temperature, blood pressure, heart rate, respiratory
rate, and the Alert Voice Pain Unresponsive (AVPU) score [7]. The AVPU score was not
reported in the electronic medical records, so we used ‘level of consciousness’ as a proxy in the
MEWS, with ‘conscious’ indicating Alert, and ‘reduced level of consciousness’ substituting
Verbal, Pain and Unresponsive. We totaled duration of intensive care unit (ICU) admission
for patients who were admitted to the ICU more than once. Readmissions within 4 weeks after
initial discharge were considered extensions of the initial hospitalization. Follow-up duration
was set to the duration until database lock for patients still admitted at the end of the study
(n = 6). We defined death as in-hospital death or palliative discharge. Patients who were dis-
charged due to clinical improvement, for medical rehabilitation, or transfer to a nursing home
were considered ‘recovered’. Patients who were transferred to a non-study hospital, who were
lost to follow-up because of other reasons, or whose reason of discharge was unknown or miss-
ing were censored.
Statistical analysis
Descriptive analyses were performed. Furthermore, we used a competing risks survival analy-
sis approach to evaluate the effect of risk factors on the time from admission to death and on
the time from admission to recovery [8, 9]. According to Noordzij et al, a competing risk
occurs ‘when subjects can experience one or more events or outcomes which ‘compete’ with
the outcome of interest’ [9]. In our study, recovery is considered a competing risk for mortality
and is taken into account as an extra outcome, whereas in standard survival analyses, patients
who recover are censored. However, the latter violates the assumption of noninformative cen-
soring, i.e. the recovered patients are not representative of those who are still admitted to the
hospital in terms of their risk of dying. Censoring recovered patients induces bias and overesti-
mation of survival curves, i.e. Kaplan Meier will estimate incidence of death with upwards
biases [8, 9]. For the competing risk analysis, we estimated univariable and multivariable
cause-specific hazard ratios (HRCS) for death and recovery for selected risk factors [5, 8].
These risk factors were pre-selected based on literature and expert opinion to be clinically rele-
vant and routinely available at time of presentation, rather than based on statistical significance
[10]. Furthermore, cumulative incidence probabilities were estimated using the Fine & Gray
approach [5, 8]. Gray’s test was used to compare equality of cumulative incidence curves
(CIFs) across subgroups [11, 12]. The proportional hazards assumption was checked by an
evaluation of the Schoenfeld residuals, as shown in S2 Fig.
Multivariable HRCS were also estimated for a subpopulation of patients with a ‘non ICU
admission policy’. The Netherlands executes a restrictive policy for ICU admission for patients
who do not wish to be admitted to the ICU, or for whom the expected chance of recovery is
thought to be too low or their overall prognosis too poor (e.g. because of comorbidity) to out-
weigh the potential harm of an ICU admission. The cause-specific hazard (CSH) model was
fitted again for this subpopulation, to assess the influence of risk factors on the outcome in
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these patients. Statistical analyses were conducted in R (v1.2.1578), using the ‘survival’, ‘surv-
miner’ and ‘cmprsk’ packages for time-to-event analyses. Laboratory values were log-trans-
formed to adjust for their skewed distribution.
Missing data
Missing data in the variables ‘non ICU admission policy, ‘COVID treatment’, ‘oxygen supple-
mentation’ and ‘ventilatory support’ were considered as ‘no’ or ‘none’, assuming that it would
be reported in the medical records if the concerning variable applied to the patient. Further-
more, missing values in the variables ‘X-ray’, ‘CT-scan’, and ‘blood culture’ were considered as
‘not performed’, assuming that the results would be reported if patients had one of these tests.
Missing values in all other variables were assumed to be missing at random (MAR) and were
imputed using multiple imputation in ten datasets with the ‘MICE’ package. Analyses were
performed on all ten imputed datasets and the results were pooled.
Results
We included 1,006 PCR-confirmed COVID-19 patients (see flowchart of inclusion in S1 Fig).
Their median age of 69 years (IQR: 58–77), most were male and presented with fever, cough
and dyspnea, as shown in Table 1. Nearly all patients had one or more comorbidities. Of all
patients, 243 (24.6%) died in-hospital or were discharged for palliative care, 689 (69.9%) recov-
ered, and 74 (7.4%) were censored. The median duration of hospital admission until death and
recovery was 6 days (IQR: 3–11) and 7 days (IQR: 4–13), respectively.
Cumulative incidence curves
The CIF curves of the total population show that the probability of death after one, two and
three weeks of hospital admission was 15.4% (95% 13.1–17.6), 20.5% (95% CI 18.0–23.0), and
22.4% (95% CI 19.8–25.0), respectively (Fig 1). The probabilities of recovery were 38.6% (95%
CI 35.5–41.6), 54.1% (95% CI 51.0–57.2), and 60.3% (95% CI 57.3–63.3), respectively. Patients
aged�70 years had a higher chance of death (p<0.001) and a lower chance of recovery
(p<0.001) than patients aged<70 years (Fig 2). Males had a lower probability of recovery
(p = 0.003) than females, but there was no statistical difference between both groups for death
(p = 0.05) (Fig 3).
Univariable and multivariable SH model
HRCS from univariable and multivariable SH models are reported in Table 2. Univariable anal-
yses showed that older age increased the risk of death: with every year increase in age, the risk
of death increased with 9% (HRCS 1.09, 95% CI 1.08–1.11), and the chances of recovery
decreased with 1% (HRCS 0.99, 95% CI 0.98–0.99). Of the comorbidities, cardiovascular dis-
ease, hypertension and pulmonary diseased increased risk of death. Patients with cardiovascu-
lar disease had a 99% increase in the risk of death (HRCS 1.99, 95% CI 1.50–2.65), and a 17%
decrease in the chances of recovery (HRCS 0.83, 95% CI 0.72–0.97). Patients with hypertension
had a 39% increase in the risk of death (HRCS 1.39, 95% CI 1.07–1.79), and a 130% increase in
chances of recovery (HRCS 2.30, 95% CI 1.98–2.68). Furthermore, patients with pulmonary
disease had a 42% increase in risk of death (HRCS 1.42, 95% CI 1.08–1.88).
In terms of medication, both chronic use of anticoagulants or antiplatelet medication as
well as ACE inhibitors or angiotensin-II receptor blockers were associated with an increased
risk of death (HRCS 2.23, 95% CI 1.73–2.87, and HRCS 1.38, 95% CI 1.07–1.79, respectively).
For symptoms, both fever and dyspnea decreased risk of death. Patients with fever had a 45%
PLOS ONE Competing risk survival analysis of COVID-19
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Table 1. Characteristics of the study population.
Total (N = 1,006) Median (IQR) or N(%) Missing N(%)
Age (years) 69 (58–77) 0 (0.0)
Sex, male 643 (63.9) 0 (0.0)
BMI 27.6 (24.7–31.0) 278 (27.6)
�1 comorbidity 904 (90.1) 3 (0.3)
Most frequent comorbidities a















Immunocompromised b 213 (21.3) 4 (0.4)
Chronic use of ACE inhibitors and/or angiotensin-II receptor blockers 336 (33.4) 1 (0.1)
Chronic use of antiplatelet medication or anticoagulants 374 (37.2) 1 (0.1)
Non ICU admission policy 312 (31.0) 26 (2.6)
Symptoms
Duration of symptoms before admission (days) 7 (5–10) 85 (8.4)
Most frequent symptoms reported at admission c
Fever
Cough









Vital signs and physical examination at time of admission
Ill appearance 399 (56.7) 302 (30.0)
Dyspnea 336 (55.5) 401 (39.9)
Fever d 459 (47.2) 33 (3.3)








Tachycardia f 278 (28.5) 30 (3.0)
Tachypnea g 573 (60.1) 53 (5.3)
Hypoxia h 149 (15.1) 22 (2.2)
Modified Early Warning Score (MEWS) i 3 (2–4) 76 (7.6)
Laboratory parameters at time of admission
Hemoglobin (mmol/L) 8.6 (7.8–9.2) 32 (3.2)
White blood cell count (�109 /L) 6.7 (5.0–9.0) 31 (3.1)
Neutrophil count (�109 /L) 5.2 (3.5–7.3) 87 (8.6)
Lymphocyte count (�109 /L) 0.9 (0.6–1.2) 84 (8.3)
Thrombocytes (�109 /L) 205 (159–268) 40 (4.0)
C-Reactive Protein (mg/L) 92.0 (47.0–147.0) 28 (2.8)
Ferritin (μg/L) 796.5 (408.8–1466.2) 206 (20.5)
D-dimer (ng/L) j 920.0 (500.0–1810.0) 194 (19.3)
Lactate dehydrogenase (U/L) 359.0 (278.5–466.5) 103 (10.2)
Procalcitonin (μg/L) 0.15 (0.08–0.33) 412 (41.0)
Creatinine (μmol/L) 84.0 (68.0–106.0) 34 (3.4)
Diagnostics
Result first PCR, positive 924 (93.8) 21 (2.1)
(Continued)
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decrease in risk of death (HRCS 0.55, 95% CI 0.42–0.72) and patients with dyspnea a 25%
decrease in risk of death (HRCS 0.75, 95% CI 0.57–0.98). In terms of diagnostics, neutrophil-
to-lymphocyte rate, creatinine levels and ferritin levels at time of admission were associated
with risk of death and risk of recovery. A ten-fold increase in the neutrophil-to-lymphocyte
rate was associated with a 58% increase in risk of death (HRCS 1.58, 95% CI 1.02–2.42) and a
35% decrease in the chance of recovery (HRCS 0.65, 95% CI 0.50–0.85). Furthermore, a ten-
fold increase in creatinine levels at time of admission were associated with a 444% increased
risk of death (HRCS 5.44, 95% CI 3.13–9.44) and a 37% decrease in chances of recovery (HRCS
0.63, 95% CI 0.40–0.99). Finally, a ten-fold increase in ferritin levels at time of admission was
associated with a 31% decrease in risk of death (HRCS 0.69, 95% CI 0.50–0.96), and a 42%
decrease in chances of recovery (HRCS 0.58, 95% CI 0.49–0.70).
Table 1. (Continued)
Total (N = 1,006) Median (IQR) or N(%) Missing N(%)
Second PCR performed












Of which: CORADS classification
1–3 (not suggestive for COVID-19)
4–5 (suggestive for COVID-19)
























Readmission after initial discharge 48 (4.8) 0 (0.0)
ICU admission 207 (21.2) 30 (3.0)
Duration of hospital admission to first ICU admission (days) 2.0 (0.5–4.0) 0 (0.0)
Duration of ICU admission (days) 17 (10–27) 13 (6.3)
Invasive ventilatory support (incl. prone position) 184 (18.4) 5 (0.5)
Complications k 640 (63.6) 0 (0.0)
Abbreviations: N = number, IQR = interquartile range, BMI = body mass index
a Comorbidities present in >10% of the population
b Immunocompromised was defined as having a haematologic malignancy, stem cell or organ transplantation, auto-immune disease, HIV/AIDS and/or use of
immunosuppressive medication.
c five most commonly reported symptoms
d Fever was defined as a body temperature� 38.0˚C.
e Hypertension was defined as: systolic blood pressure�140 mmHg and diastolic blood pressure�90 mmHg.
Hypotension was defined as: systolic blood pressure<90 mmHg and diastolic blood pressure <60 mmHg.
f Tachycardia was defined as a heart rate >100 bpm.
g Tachypnea was defined as a respiratory rate >20 bpm.
h Hypoxia was defined as a peripheral oxygen saturation <90%.
i Adjusted version of Modified Early Warning Score.
j D-dimer was tested within 24h of hospital admission.
k The most common complications included acute kidney injury (18.2%), delirium (13.0%), and new onset/episode of atrial fibrillation (9.6%).
https://doi.org/10.1371/journal.pone.0249231.t001
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In multivariable analyses, the following factors were associated with risk of death: age,
immunocompromised state, chronic use of anticoagulants or antiplatelet medication, fever,
MEWS, lactate dehydrogenase values at time of admission, and ferritin values at time of
admission. Firstly, with every year increase in age, the risk of death increased with 10% (HRCS
1.10, 95% CI 1.08–1.12), and the chances of recovery decreased with 1% (HRCS 0.99, 95% CI
0.98–0.99). In other words, if in two patients all variables except for age are the same, the
patient who is one year older has a 10% higher risk of dying. Furthermore, patients with
immunocompromised state had a 46% increased risk of death (HRCS 1.46, 95% CI 1.08–1.98),
and 24% decrease in chances of recovery (HRCS 0.76, 95% CI 0.62–0.93). Moreover, patients
that used anticoagulants or antiplatelet medication had a 38% increase in risk of death (HRCS
1.38, 95% CI 1.01–1.88). Furthermore, patients with fever had a 30% decrease in risk of death
(HRCS 0.70, 95% CI 0.52–0.95). In terms of diagnostics, with every unit increase of MEWS,
the risk of death increased with 9% (HRCS 1.09, 95% CI 1.01–1.18). Moreover, a ten-fold
increase in lactate dehydrogenase values at time of admission was associated with a 568%
increase in risk of death (HRCS 6.68, 95% CI 1.95–22.8), and a 75% decrease in chances of
recovery (HRCS 0.25, 95% CI 0.13–0.48). Finally, a ten-fold increase in ferritin values at time
of admission was associated with a 23% decrease in chances of recovery (HRCS 0.77, 95% CI
0.60–0.99).
Fig 1. Cumulative incidence plot of death and recovery in the total population. The probability of death conditional on not having recovered after one,
two and three weeks of hospital admission was 15.4% (95% 13.1–17.6), 20.5% (95% CI 18.0–23.0), and 22.4% (95% CI 19.8–25.0), respectively. The
probability of recovery conditional on not having died after one, two and three weeks of hospital admission was 38.6% (95% CI 35.5–41.6), 54.1% (95% CI
51.0–57.2), and 60.3% (95% CI 57.3–63.3).
https://doi.org/10.1371/journal.pone.0249231.g001
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Non ICU admission policy
In this study, 318 (31.5%) patients had a non ICU admission policy, of whom 199 (62.6%)
were male, with a median age of 79 years (IQR 74–83), and a median MEWS of 2 (IQR 2–4).
Of these patients, 151 (47.5%) recovered, 158 (49.7%) died and 9 (2.8%) were censored. Multi-
variable analyses revealed no statistically significant associations with risk of death, but that
patients with longer symptom duration had an increased chance of recovery (HRCS 1.02, 95%
CI 1.00–1.04) and patients with symptoms of dyspnea had a decreased chance of recovery
(HRCS 0.65, 95% CI 0.44–0.96).
Discussion
Summary of findings
In this Dutch hospital population, approximately a quarter of all COVID-19 patients died after
a median hospital admission of six days during the first wave of the epidemic. Using a compet-
ing risk approach, we identified age, comorbidities, such as cardiovascular diseases, symptoms,
and abnormal laboratory values as the most important risk factors in univariate analyses. After
adjusting for all relevant factors at baseline, we found that higher age, immunocompromised
state, chronic use of anticoagulants or antiplatelet medication, higher MEWS, and higher
Fig 2. Cumulative incidence plot of death and recovery in the total population, separated by age group. Gray’s test indicated a significant difference
between two groups for both death (p<0.001) and recovery (p<0.001). The probability of death for patients aged<70 years after one, two and three weeks
of hospital admission was 3.6% (95% CI 2–5.2), 5.4% (95% CI 3.4–7.4), and 6.5% (95% CI 4.3–8.6), respectively, whereas for patients aged�70 years, the
probability of death was 27.8% (95% CI 23.8–31.8), 36.4% (95% CI 32.1–40.7), and 39.2% (95% CI 34.8–43.5), respectively.
https://doi.org/10.1371/journal.pone.0249231.g002
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values of LDH at time of hospital admission were associated with increased risk of death. On
the other hand, fever at time of admission was associated with lower mortality. Male sex was
not a significant risk factor for mortality.
Interpretation of results and comparison to literature
Conventional survival analyses do not take competing risks into account, which leads to biased
mortality estimates and to overestimation of survival curves. Using the competing risk
approach, we took into account that patients who recovered were no longer at the same risk of
dying than those who remained hospitalized, resulting in less biased mortality estimates. Even
though death or recovery are the two possible final outcomes of the disease, the time to death
and time to recovery may not the same (i.e. time to death was generally shorter than time to
recovery). In addition, 10% of our patients were censored due to transfer to other hospitals. As
a result, the risk factors influencing death may differ from risk factors for recovery [13]. For
example, we identified strong risk factors that both increased the risk of dying and reduced the
recovery risk, namely higher age, immunosuppression and high LDH values at admission. At
the same time, use of anticoagulant or antiplatelet medication and a high MEWS were only
associated with an increased risk of dying. Fever at admission reduced this risk, and ferritin
showed equivocal results, reducing the risk of death as well as the risk of recovery.
Fig 3. Cumulative incidence plot of death and recovery in the total population, separated by sex. Gray’s test indicated a statistically significant
difference between both groups for recovery (p = 0.003), but not for death (p = 0.050). The probability of death for females after one, two and three weeks of
hospital admission was 12.5% (95% CI 10.0–17.1), 17.6% (95% CI 13.7–21.6), and 19.1% (95% CI 15.0–23.2), respectively, whereas for males the probability
of death was 16.4% (95% CI 13.5–19.3), 22.1% (95% CI 18.9–25.4), and 24.3% (95% CI 20.9–27.6), respectively.
https://doi.org/10.1371/journal.pone.0249231.g003
PLOS ONE Competing risk survival analysis of COVID-19
PLOS ONE | https://doi.org/10.1371/journal.pone.0249231 March 26, 2021 9 / 14
In our study population, approximately 25% of all patients died, which is consistent with
other studies [14, 15]. Our study showed that age and higher MEWS at time of admission were
risk factors for in-hospital mortality, which is in line with results of many other studies [4, 16–
18]. Higher blood LDH levels at time of admission increased the probability of death and
decreased the chance of recovery, which is in line with a growing body of evidence [4, 19, 20].
We included both cardiovascular disease and hypertension in our model, which may be sub-
ject to collinearity. However, a sensitivity analyses excluding hypertension from the model did
not change our estimates and standard errors, showing that our reported estimates are valid.
We found immunosuppression as a risk factor for mortality. This has been reported previ-
ously, although the exact role of the immune system in COVID-19 is complex [16, 21, 22].
Poor outcome could be determined by a declining immune system less able to clear the virus,
but lung tissue damage in severe cases could also be caused by an exaggerated immune
Table 2. Univariable and multivariable cause-specific hazard ratios (HRCS) including 95% confidence intervals for death and recovery.
Univariable Multivariable
Death Recovery Death Recovery
Age (years) 1.09 (1.08–1.11) � 0.99 (0.98–0.99) � 1.10 (1.08–1.12) � 0.99 (0.98–0.99) �
Sex, male 1.15 (0.88–1.52) 0.80 (0.68–0.93) � 1.07 (0.79–1.47) 0.90 (0.75–1.08)
BMI 0.99 (0.96–1.01) 1.01 (0.99–1.03) 1.01 (0.98–1.04) 1.01 (0.99–1.03)
Diabetes Mellitus 1.23 (0.93–1.63) 0.89 (0.74–1.07) 1.17 (0.86–1.59) 0.85 (0.69–1.04)
Cardiovascular disease (incl. hypertension) 1.99 (1.50–2.65) � 0.83 (0.72–0.97) � 1.05 (0.69–1.59) 0.71 (0.54–0.93) �
Hypertension 1.39 (1.07–1.79) � 2.30 (1.98–2.68) � 0.78 (0.56–1.10) 1.15 (0.90–1.48)
Pulmonary disease 1.42 (1.08–1.88) � 1.01 (0.85–1.21) 1.33 (0.98–1.80) 0.88 (0.73–1.07)
Immunocompromised a 1.31 (0.99–1.74) 0.87 (0.72–1.05) 1.46 (1.08–1.98) � 0.76 (0.62–0.93) �
Chronic use of anticoagulant or antiplatelet medication 2.23 (1.73–2.87) � 1.01 (0.86–1.18) 1.38 (1.01–1.88) � 1.15 (0.93–1.43)
Chronic use of ACE inhibitors and/or angiotensin II receptor blockers 1.38 (1.07–1.79) � 0.97 (0.83–1.14) 0.99 (0.74–1.32) 1.09 (0.88–1.33)
Chest X-Ray
Performed, not suggestive for COVID-19 Ref Ref Ref Ref
Performed, suggestive for COVID-19 0.96 (0.59–1.55) 0.96 (0.71–1.28) 1.07 (0.63–1.80) 1.52 (1.05–2.19) �
Not performed 0.76 (0.48–1.20) 1.02 (0.75–1.39) 0.90 (0.54–1.48) 1.18 (0.82–1.70)
CT scan severity score 0.99 (0.97–1.02) 0.95 (0.93–0.97) � 1.01 (0.98–1.05) 0.97 (0.95–0.99) �
Symptom duration (days) 0.98 (0.95–1.00) 1.01 (1.00–1.02) 0.98 (0.96–1.01) 1.01 (1.00–1.02) �
Symptoms, fever 0.55 (0.42–0.72) � 0.95 (0.79–1.15) 0.70 (0.52–0.95) � 1.05 (0.85–1.30)
Symptoms, dyspnea 0.75 (0.57–0.98) � 0.94 (0.80–1.11) 0.77 (0.58–1.03) 1.01 (0.84–1.21)
Modified Early Warning Score (MEWS) b 1.06 (0.99–1.14) 0.95 (0.91–1.00) � 1.09 (1.01–1.18) � 0.97 (0.93–1.02)
Neutrophil-to-lymphocyte rate c 1.58 (1.02–2.42) � 0.65 (0.50–0.85) � 0.97 (0.59–1.60) 1.01 (0.74–1.38)
Lactate dehydrogenase (U/L) c 1.67 (0.76–3.65) 0.16 (0.10–0.25) � 6.68 (1.95–22.8) � 0.25 (0.13–0.48) �
Creatinine (μmol/L) c 5.44 (3.13–9.44) � 0.63 (0.40–0.99) � 1.84 (0.87–3.90) 1.17 (0.69–1.99)
Procalcitonin (μg/L) c 1.27 (0.98–1.64) 0.78 (0.68–0.90) � 1.04 (0.76–1.41) 0.88 (0.75–1.03)
C-reactive protein (mg/L) c 1.16 (0.82–1.63) 0.61 (0.51–0.74) � 1.25 (0.79–2.00) 0.88 (0.69–1.11)
Ferritin (μg/L) c 0.69 (0.50–0.96) � 0.58 (0.49–0.70) � 0.66 (0.43–1.02) 0.77 (0.60–0.99) �
D-dimer (ng/L) d 1.10 (0.94–1.30) 0.88 (0.83–0.93) � 0.99 (0.84–1.16) 0.94 (0.87–1.00)
� Statistically significant, i.e. p<0.05.
a Immunocompromised was defined as having an hematologic malignancy, stem cell or organ transplantation, auto-immune disease, HIV/AIDS and/or use of
immunosuppressive medication.
b Adjusted version of Modified Early Warning Score.
c These laboratory variables are log-transformed. HRs should be interpreted for a 10-fold increase in the concerning variable, rather than a one unit increase.
d D-dimer is determined within 24h of hospital admission.
https://doi.org/10.1371/journal.pone.0249231.t002
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response, rather than damage inflicted by the virus itself [23–26]. Consequently, immunocom-
promised patients may be protected from this type of hyperinflammation [21, 27]. We found
that chronic use of anticoagulants or antiplatelet medication was associated with increased risk
of death. Although this may be partially explained by the fact that these medications are used
by patients with cardiovascular disease, which has been reported as an individual risk factor
for in-hospital mortality [4], anticoagulant and/or antiplatelet medication remained an inde-
pendent risk factor for death in our multivariable analyses. Thromboembolic events are fre-
quently reported in association with severe COVID-19 disease and mortality [28, 29], and
current guidelines suggest prophylactic anticoagulants in all hospitalized COVID-19 patients
if not contraindicated. However, studies have reported conflicting results regarding the effect
of anticoagulants/antiplatelet medication on COVID-19 mortality [30], ranging from a protec-
tive effect [31] to a harmful effect [32, 33], or no association [31, 34]. Prospective studies and
RCTs are needed to explore the true effects of these medications in hospitalized COVID-19
patients.
Findings of a living systematic review of 23 prognostic studies about COVID-19 mortality
indicated that age, immunocompromising comorbidities, composite scores of vital parameters
and blood LDH are frequently reported predictors of in-hospital mortality, similar to our find-
ings [4]. Blood ferritin levels and anticoagulants or antiplatelet medication were scarcely
reported [4]. On the other hand, male sex and comorbidities, such as cardiovascular and pul-
monary diseases, that were significantly associated with in-hospital mortality in our univari-
able but not multivariable analyses, were frequently reported in other prognostic studies. This
is an important finding and shows that many of these risk factors are interacting with each
other. Last, we found no increased risk of dying in patients with male sex, high BMI or diabe-
tes, which are also risk factors that have been reported previously. Larger studies may be
needed to reveal additional risk factors of clinical importance.
Strengths and limitations
A strength of this study is the large, multicenter population in an area in which infections were
clustered. We analyzed mortality in COVID-19 patients using a competing risk approach,
leading to more accurate risk estimates for mortality than when using conventional survival
analysis. As previously explained, conventional survival analyses may have resulted in biased
estimates and Kaplan-Meier curves presenting overestimated incidence of death. There were
some limitations to this study. First, approximately 10% of patients in our study were censored,
mainly due to frequent transfer of patients. However, this was considered within acceptable
limits [35–37]. Second, our data consisted of routinely collected data, resulting in missing val-
ues in several variables. We used multiple imputation to minimize associated bias. The advan-
tage of routinely collected data is that the study’s predictors are readily available and be used in
clinical practice without extra effort. All reported predictors are variables measured at time of
hospital admission, which means that these factors can be used to identify patients in need of
more intensive care and monitoring in an early stage of hospitalization. Finally, data were col-
lected in multiple centers with differences in manner of reporting in medical records and dif-
ferences in clinical management. The advantage of this multicenter approach is that it
increased the generalizability of our findings.
Conclusion
Using a robust, competing risk survival analysis, our study confirmed specific risk factors for
in-hospital COVID-19 mortality, adding rigor to the current knowledge of risk factors. We
confirmed that age, immunocompromised state, use of anticoagulants or antiplatelet
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medication, MEWS, blood LDH are important risk factors for death in hospitalized COVID-
19 patients. The risk factors we identified are mostly in line with the growing body of evidence
on COVID-19, although we did not find evidence for increased mortality risk in male patients
or those with high BMI or diabetes. All identified risk factors are routinely available at time of
admission. They can be used to guide clinical decisions on intense monitoring of patients in-
hospital, or to select patients that may benefit most from new treatments. In addition, the
more general risk factors like age and comorbidities could be used to prioritize patients for
vaccinations in current times where vaccines are still scarce. Lastly, our risk factor analysis pro-
vides further input for international prediction research for mortality of COVID-19.
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